Advertisement
UK markets closed
  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     
  • HANG SENG

    18,313.86
    -165.51 (-0.90%)
     
  • CRUDE OIL

    78.94
    +0.56 (+0.71%)
     
  • GOLD FUTURES

    2,327.70
    +3.50 (+0.15%)
     
  • DOW

    38,974.38
    +90.12 (+0.23%)
     
  • Bitcoin GBP

    49,839.93
    -1,184.90 (-2.32%)
     
  • CMC Crypto 200

    1,320.44
    +25.77 (+1.99%)
     
  • NASDAQ Composite

    16,296.02
    -36.54 (-0.22%)
     
  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     

What Analysts Think about Ionis

What Analysts Think about Ionis

In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.